Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
483.00    2.40 (0.50%)
Bid:
482.80
Ask:
483.80
Spread: 1.00 (0.207%)
Market Cap: £2.49b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Third Quarter Trading Update

15 Feb 2017 07:00

RNS Number : 8892W
QinetiQ Group plc
15 February 2017
 

 

 

 

QinetiQ Group plc

 

Third Quarter Trading Update

 

QinetiQ Group plc ('QinetiQ' or 'the Group') today issues a trading update for the third quarter during which it has made encouraging progress in the implementation of its strategy to drive future growth.

 

Strategy update

 

On 2 December 2016, QinetiQ was awarded a £1bn amendment to its Long Term Partnering Agreement (LTPA) with the UK Ministry of Defence (MOD) which commits approximately half of the core LTPA revenues until 31 March 2028. The Group is already delivering against its commitment to modernise UK air ranges and the Empire Test Pilots' School at MOD Boscombe Down, including the purchase of new aircraft to meet the future training needs of test pilots and aircrew.

 

On 21 December 2016, the Group agreed and completed the acquisition of Meggitt Target Systems. The business, now renamed QinetiQ Target Systems, generates 90 per cent of its revenue from outside the UK and forms part of QinetiQ's International business unit. It will be reported in the Group's Global Products division.

 

On 5 January 2017, the Dragonfire consortium - led by MBDA and including QinetiQ as well as other industry partners - was awarded a £30m programme by the UK MOD to deliver a Laser Directed Energy Weapon (LDEW) Capability Demonstrator. QinetiQ's role is to provide the high-powered laser technology for the programme and conduct trials at various ranges over land and water.

 

Trading update

 

Underlying trading for the Group was as expected during the third quarter.

 

In EMEA Services, revenue under contract for this financial year is similar to the same time last year with resilient margins. As stated previously, the division's performance as a whole is expected to remain steady this year.

 

The Group's Global Products division has shorter order cycles than EMEA Services. Revenue under contract is slightly ahead of this time last year driven by improved order inflow in QinetiQ North America, although the division's performance remains dependent on the timing and shipment of key orders.

 

Balance sheet

 

The incremental capital expenditure associated with the amendment to the LTPA contract is expected to be in the region of £10m this year.

 

The Group is completing the previously announced £50m share repurchase with £13m of the buyback remaining as at 10 Feb 2017.

 

Outlook

Overall, the Board's expectations for Group performance in the current financial year remain unchanged from those set out in QinetiQ's interim results announcement dated 17 November 2016.

 

QinetiQ will announce its preliminary annual results for the year ending 31 March 2017 on 25 May 2017.

 

ENDS

 

Notes to Editors:

 

Download the QinetiQ investor relations app for iPad and iPhone from the App Store.

 

Listed on the London Stock Exchange (LSE: QQ.L), QinetiQ is a leading science and engineering company operating primarily in the defence, security and aerospace markets. Our customers are predominantly government organisations including defence departments, as well as international customers in other targeted sectors.

 

For more information see www.QinetiQ.com

 

Follow us on twitter @QinetiQ

 

For further information please contact:

Investor relations:

David Bishop, QinetiQ

+44 (0) 7920 108675

Media relations:

Chris Barrie, Citigate Dewe Rogerson

+44 (0) 7968 727289

QinetiQ press office

+44 (0) 1252 393500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDZLFFDLFXBBZ
Date   Source Headline
13th Jul 20203:51 pmRNSQinetiQ enters next phase of growth in the US
10th Jul 202011:52 amRNSDirector/PDMR Shareholding
1st Jul 202010:50 amRNSDirector/PDMR Shareholding
1st Jul 202010:49 amRNSTotal Voting Rights
1st Jul 202010:46 amRNSDirector/PDMR Shareholding
25th Jun 20207:00 amRNSDisposal of Boldon James to HelpSystems
23rd Jun 202011:46 amRNSDirector/PDMR Shareholding
12th Jun 202010:48 amRNSAnnual Financial Report
10th Jun 202012:31 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSPreliminary Results
19th May 20204:05 pmRNSDirectorate Change
12th May 202011:22 amRNSDirector/PDMR Shareholding
1st May 202011:16 amRNSBlock listing Interim Review
30th Apr 20207:00 amRNSAppointment of Broker
29th Apr 20204:17 pmRNSHolding(s) in Company
15th Apr 202010:35 amRNSDirector/PDMR Shareholding
1st Apr 20209:33 amRNSHolding(s) in Company
1st Apr 20207:00 amRNSTrading and COVID-19 update
20th Mar 202010:21 amRNSDirector/PDMR Shareholding
18th Mar 20202:13 pmRNSHolding(s) in Company
10th Mar 202011:13 amRNSDirector/PDMR Shareholding
11th Feb 202010:53 amRNSDirector/PDMR Shareholding
10th Feb 202012:14 pmRNSDirector/PDMR Shareholding
6th Feb 20209:40 amRNSHolding(s) in Company
4th Feb 20207:00 amRNSThird Quarter Trading Update
13th Jan 202012:09 pmRNSDirector/PDMR Shareholding
20th Dec 20191:24 pmRNSQinetiQ completes acquisition of MTEQ
10th Dec 20199:48 amRNSDirector/PDMR Shareholding
9th Dec 20199:04 amRNSHolding(s) in Company
28th Nov 20199:25 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSInterim Results
12th Nov 201911:59 amRNSDirector/PDMR Shareholding
1st Nov 20199:30 amRNSBlock listing Interim Review
10th Oct 201911:37 amRNSDirector/PDMR Shareholding
2nd Oct 20197:00 amRNSQinetiQ acquisition of MTEQ
10th Sep 201912:06 pmRNSDirector/PDMR Shareholding
2nd Sep 201910:38 amRNSDirector/PDMR Shareholding
16th Aug 20191:35 pmRNSHolding(s) in Company
12th Aug 201912:35 pmRNSDirector/PDMR Shareholding
24th Jul 201912:11 pmRNSResult of AGM
24th Jul 20197:00 amRNSFirst Quarter Trading Update
10th Jul 20193:52 pmRNSDirector/PDMR Shareholding
2nd Jul 20194:05 pmRNSDirector/PDMR Shareholding
2nd Jul 20193:19 pmRNSDirector Declaration
1st Jul 20194:53 pmRNSDirector/PDMR Shareholding
12th Jun 201911:11 amRNSAnnual Financial Report
11th Jun 201911:19 amRNSDirector/PDMR Shareholding
29th May 201911:59 amRNSDirector/PDMR Shareholding
23rd May 20197:00 amRNSPreliminary Results
10th May 201910:47 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.